首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >PNAS Plus: Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies
【2h】

PNAS Plus: Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies

机译:PNAS Plus:显示工程化糖基的外膜囊泡可引发保护性抗体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The O-antigen polysaccharide (O-PS) component of lipopolysaccharides on the surface of gram-negative bacteria is both a virulence factor and a B-cell antigen. Antibodies elicited by O-PS often confer protection against infection; therefore, O-PS glycoconjugate vaccines have proven useful against a number of different pathogenic bacteria. However, conventional methods for natural extraction or chemical synthesis of O-PS are technically demanding, inefficient, and expensive. Here, we describe an alternative methodology for producing glycoconjugate vaccines whereby recombinant O-PS biosynthesis is coordinated with vesiculation in laboratory strains of Escherichia coli to yield glycosylated outer membrane vesicles (glycOMVs) decorated with pathogen-mimetic glycotopes. Using this approach, glycOMVs corresponding to eight different pathogenic bacteria were generated. For example, expression of a 17-kb O-PS gene cluster from the highly virulent Francisella tularensis subsp. tularensis (type A) strain Schu S4 in hypervesiculating E. coli cells yielded glycOMVs that displayed F. tularensis O-PS. Immunization of BALB/c mice with glycOMVs elicited significant titers of O-PS–specific serum IgG antibodies as well as vaginal and bronchoalveolar IgA antibodies. Importantly, glycOMVs significantly prolonged survival upon subsequent challenge with F. tularensis Schu S4 and provided complete protection against challenge with two different F. tularensis subsp. holarctica (type B) live vaccine strains, thereby demonstrating the vaccine potential of glycOMVs. Given the ease with which recombinant glycotopes can be expressed on OMVs, the strategy described here could be readily adapted for developing vaccines against many other bacterial pathogens.
机译:革兰氏阴性细菌表面的脂多糖的O抗原多糖(O-PS)既是毒力因子,又是B细胞抗原。 O-PS引发的抗体通常可以防止感染。因此,已证明O-PS糖缀合物疫苗可用于对抗许多不同的病原细菌。然而,用于O-PS的天然提取或化学合成的常规方法在技术上要求高,低效且昂贵。在这里,我们描述了生产糖缀合物疫苗的另一种方法,其中重组O-PS生物合成与大肠杆菌实验室菌株中的囊泡形成协调,以产生装饰有病原体模拟糖基的糖基化外膜囊泡(glycOMV)。使用这种方法,产生了与八种不同的病原菌相对应的glycOMV。例如,从高毒性的弗朗西斯菌图拉菌亚种表达17kb的O-PS基因簇。在高泡性大肠杆菌细胞中,Tularensis(A型)菌株Schu S4产生了显示T.ularularensis O-PS的glycOMV。用glycOMV免疫BALB / c小鼠会引起大量的O-PS特异性血清IgG抗体以及阴道和支气管肺泡IgA抗体效价。重要的是,糖OMVs在随后用土拉弗朗西斯菌Schu S4攻击后可显着延长生存期,并提供了针对两种不同的土拉弗雷亚菌亚种攻击的完全保护。 holarctica(B型)活疫苗株,从而证明了糖OMV的疫苗潜力。考虑到重组糖基可以在OMV上表达的难易程度,此处描述的策略可轻松用于开发针对许多其他细菌病原体的疫苗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号